| Category | Amount | Net Investment Income | Adjusted Net Income | Disbursements for Charitable Purposes |
|---|---|---|---|---|
| LEGAL AND ACCOUNTING | 23,612 | 11,806 | 11,806 |
| Name | Date Acquired | How Acquired | Date Sold | Purchaser Name | Gross Sales Price | Basis | Basis Method | Sales Expenses | Total (net) | Accumulated Depreciation |
|---|---|---|---|---|---|---|---|---|---|---|
| PARTNERSHIP FLOWTHROUGH - UBI - SHORT-TERM | PURCHASED | 6 | COST | 0 | 6 | |||||
| PARTNERSHIP FLOWTHROUGH - UBI - LONG-TERM | PURCHASED | 17 | COST | 0 | 17 |
| Identifier | Return Reference | Explanation |
|---|---|---|
| DONOR ADVISED FUNDS | FORM 990-PF, PART VII-A, LINE 12 | NO DISTRIBUTIONS WERE MADE TO OUR DONOR ADVISED FUND AT CHATTANOOGA CHRISTIAN COMMUNITY FOUNDATION (DBA THE GENEROSITY TRUST), EIN# 62-1536731 DURING THE 2024 TAX YEAR. THE TRUST RETAINED ADVISORY PRIVILEGES. CHATTANOOGA CHRISTIAN COMMUNITY FOUNDATION ("CCCF") IS A SECTION 509(A)(1) ORGANIZATION AS REFERRED TO IN SECTION 170(B)(1)(A)(VI). THE ENTIRE AMOUNT WAS TREATED AS A QUALIFYING DISTRIBUTION IN PART XV, LINE 3, CONTRIBUTIONS, GIFTS, GRANTS PAID. THE DONOR-ADVISED FUND AGREEMENT BETWEEN THE CHRISTIAN EDUCATION CHARITABLE TRUST AND CCCF INCLUDES THE FOLLOWING:"CCCF SHALL RECEIVE, REVIEW AND CONSIDER WRITTEN RECOMMENDATIONS FROM THE COMMITTEE CONCERNING GRANTS MADE FROM THE FUND AND ANY CONDITIONS WHICH SHOULD BE PLACED UPON SUCH GRANTS. THE FINAL DECISION CONCERNING SUCH MATTERS SHALL BE MADE BY THE BOARD OF DIRECTORS OF CCCF.""NO INCOME OR PRINCIPAL OF THE FUND SHALL BE USED FOR ANY PURPOSE OR PAID TO ANY BENEFICIARY IF SUCH USE OR PAYMENT WOULD NOT BE PERMITTED BY THE INTERNAL REVENUE CODE (THE "CODE") OR REGULATIONS THEREUNDER FOR AN ORGANIZATION DESCRIBED IN SECTION 501(C)(3) OF THE CODE, TO WHICH CONTRIBUTIONS ARE DEDUCTIBLE UNDER SECTION 170(C)(2) OF THE CODE." |
| Name of Stock | End of Year Book Value | End of Year Fair Market Value |
|---|---|---|
| FRANCIS MEDICAL | 186,000 | 186,000 |
| FRANCIS MEDICAL 8110 SHARES COMMON STOCK | 8,110 | 8,110 |
| UBS PUBLICLY TRADED SECURITIES | 7,470,996 | 8,659,779 |
| Category/ Item | Listed at Cost or FMV | Book Value | End of Year Fair Market Value |
|---|---|---|---|
| AERIAL BIOPHARMA, LLC | AT COST | 34,504 | 0 |
| ARRIVO BIOVENTURES LLC | AT COST | 394,179 | 1,404,220 |
| BI FUND I, A SERIES OF PATHBREAKER SPV, LP (BIOBOT ANALYTICS) | AT COST | 50,432 | 0 |
| BOW RIVER CAPITAL 2017-QP FUND, LP | AT COST | 270,148 | 551,029 |
| C-III RECOVERY FUND II LP | AT COST | 174,993 | 170,658 |
| DYNAMO FUND I, LP | AT COST | 182,098 | 1,382,565 |
| DYNAMO FUND II, LP | AT COST | 364,276 | 436,538 |
| DYNAMO OPPORTUNITY FUND I L.P. | AT COST | 475,696 | 682,801 |
| DYNAMO-GATIK LLC | AT COST | 45,122 | 89,017 |
| DYNAMO-SKUPOS, LLC | AT COST | 29,560 | 29,559 |
| DYNAMO-STORD SPV II, LLC | AT COST | 100,265 | 416,163 |
| DYNAMO-SVT ROBOTICS SPV II LLC | AT COST | 12,680 | 12,402 |
| DYNAMO-VECTOR LLC | AT COST | 18,740 | 28,508 |
| ESO VENTURE FUND V | AT COST | 183,736 | 242,307 |
| FR FUND I, A SERIES OF PATHBREAKER SPV II, LP (FRAMEWORK) | AT COST | 116,742 | 149,383 |
| FULCRUM GROWTH FUND III QP, LLC | AT COST | 164,686 | 344,830 |
| G SQUARED VI, LP | AT COST | 523,528 | 724,719 |
| GOODWATER CAPITAL IV, LP | AT COST | 283,746 | 264,466 |
| GOODWATER INFINITY II, LP | AT COST | 425,341 | 460,104 |
| GRAYMATTER ROBOTICS SPV TOTAL | AT COST | 76,091 | 141,000 |
| HYPHEN SPV SERIES A TOTAL | AT COST | 56,039 | 94,000 |
| H2OEY VENTURES | AT COST | 209,564 | 212,529 |
| H2OEY VENTURES II, LLC | AT COST | 503,609 | 510,000 |
| IR B FUND, A SERIES OF PATHBREAKER SPV, | AT COST | 100,185 | 0 |
| IR C, A SERIES OF PATHBREAKER SPV, LP (IRON OX) | AT COST | 50,057 | 0 |
| IRONOX CN STAR, LP | AT COST | 55,925 | 7,522 |
| IR-1027 FUND VI, A SERIES OF PATHBREAKER SPV, LP | AT COST | 35,493 | 35,827 |
| KERN CAPITAL LLC | AT COST | 100,000 | 100,000 |
| KERN DIAGNOSTICS | AT COST | 65,000 | 21,645 |
| KERN ODYSSEUS LLC | AT COST | 100,000 | 100,000 |
| SOLAS - MACLELLAN GROUP (FKA KNOPP BIOSCIENCES LLC) | AT COST | 206,712 | 1,697,521 |
| MIDNIGHT PHARMA LLC | AT COST | 15,514 | 55,590 |
| NEXTGEN VENTURES FUND II QP LP | AT COST | 185,220 | 269,613 |
| ON FUND I, A SERIES OF PATHBREAKER SPV, LP (HYPHEN) | AT COST | 100,638 | 421,600 |
| ON FUND II, A SERIES OF PATHBREAKER SPV, LP (HYPHEN) | AT COST | 50,269 | 78,800 |
| OR FUND I, A SERIES OF PATHBREAKER SPV, | AT COST | 75,508 | 75,509 |
| PATHBREAKER VENTURES FUND II LP | AT COST | 349,123 | 684,718 |
| PORTFOLIO ADVISORS SECONDARY FUND III, L.P. | AT COST | 225,115 | 343,331 |
| RA CAPITAL HEALTHCARE FUND LP | AT COST | 20,557 | 34,253 |
| RELEVANCE CAPITAL III, LP | AT COST | 255,721 | 503,616 |
| RESOLUTE CAPITAL PARTNERS FUND IV, LP | AT COST | 407,917 | 440,282 |
| RIVER VII LP | AT COST | 318,883 | 571,655 |
| RIVER VIII | AT COST | 159,958 | 180,903 |
| RU FUND III, A SERIES OF PATHBREAKER SPV, | AT COST | 75,111 | 0 |
| SATURN FIVE FRONTIER LLC | AT COST | 558,735 | 690,305 |
| SI FUND III, A SERIES OF PATHBREAKER SPV, LP (SIMBE ROBOTICS) | AT COST | 108,754 | 128,248 |
| SI FUND IV, A SERIES OF PATHBREAKER SPV, LP (SIMBE ROBOTICS) | AT COST | 52,136 | 255,838 |
| SOVEREIGNS CAPITAL LOWER MIDDLE MARKET FUND II LP | AT COST | 240,116 | 446,496 |
| SIGNIA VENTURE PARTNERS III, LP | AT COST | 395,434 | 487,245 |
| TO FUND I, A SERIES OF PATHBREAKER SPV, LP (TORIC LABS) | AT COST | 100,970 | 209,482 |
| VALOR OPPORTUNITY FUND I, LP | AT COST | 317,447 | 372,710 |
| VALOR OPPORTUNITY FUND II, LP | AT COST | 117,378 | 127,324 |
| VALOR VENTURE FUND II, L.P. | AT COST | 418,081 | 2,110,395 |
| VALOR VENTURE FUND III, L.P. | AT COST | 459,426 | 759,614 |
| VALOR VENTURE FUND IV, L.P. | AT COST | 188,939 | 223,684 |
| Description | Beginning of Year - Book Value | End of Year - Book Value | End of Year - Fair Market Value |
|---|---|---|---|
| PRIVATE EQUITY DISTRIBUTION RECEIVABLE | 18,104 | 18,104 |
| Description | Revenue and Expenses per Books | Net Investment Income | Adjusted Net Income | Disbursements for Charitable Purposes |
|---|---|---|---|---|
| BANK AND WIRE FEE | 1,761 | 1,761 | 0 | |
| INSURANCE | 4,954 | 248 | 4,706 | |
| OFFICE EXPENSE | 1,117 | 56 | 1,061 | |
| GUEST EXPENSE AND MEALS | 6,868 | 0 | 6,868 | |
| BOARD AND TRUSTEE EXPENSES | 21,891 | 0 | 21,891 | |
| PARTNERSHIPS PORTFOLIO DEDUCTIONS | 233,910 | 233,910 | 0 | |
| OTHER PARTNERSHIPS DEDUCTIONS | 12,928 | 12,928 | 0 | |
| NONDEDUCTIBLE EXPENSES FROM PARTNERSHIPS | 3,586 | 0 | 0 | |
| TRAINING AND EDUCATION | 2,226 | 0 | 2,226 |
| Description | Revenue And Expenses Per Books | Net Investment Income | Adjusted Net Income |
|---|---|---|---|
| PARTNERSHIPS RENTAL INCOME | 148 | 148 | 148 |
| PARTNERSHIPS ROYALTIES | 13 | 13 | 13 |
| PARTNERSHIPS SUBPART F INCOME | 1 | 1 | 1 |
| PARTNERSHIPS OTHER PORTFOLIO INCOME | 63 | 63 | 63 |
| PARTNERSHIPS OTHER INCOME | 641 | 641 | 641 |
| OTHER MISC INCOME | 299 | 299 | 299 |
| PARTNERSHIPS ORDINARY INCOME | -52,110 | -52,110 | -52,110 |
| UNRELATED BUSINESS INCOME FROM PASSTHROUGH | 178,205 | 178,205 |
| Category | Amount | Net Investment Income | Adjusted Net Income | Disbursements for Charitable Purposes |
|---|---|---|---|---|
| OTHER CHARITABLE CONSULTING | 30,000 | 0 | 30,000 | |
| INVESTMENT AND MANAGEMENT FEES | 44,774 | 44,774 | 0 |
| Category | Amount | Net Investment Income | Adjusted Net Income | Disbursements for Charitable Purposes |
|---|---|---|---|---|
| FOREIGN TAXES WITHHELD FROM DIVIDENDS | 6,239 | 6,239 | 0 | |
| FOREIGN TAXES WITHHELD FROM PARTNERSHIP INCOME | 59 | 59 | 0 | |
| EXCISE TAX | 14,250 | 0 | 0 |